The Market Reports

Synopsis
The global market for Intravitreal Injectable was estimated to be worth US$ 17970 million in 2024 and is forecast to a readjusted size of US$ 28700 million by 2031 with a CAGR of 7.1% during the forecast period 2025-2031.
Intravitreal injectables are sterile pharmaceutical formulations administered directly into the vitreous humor of the eye using a fine needle. This route of administration allows for targeted delivery of medications—such as anti-VEGF agents, corticosteroids, or antibiotics—into the posterior segment of the eye, ensuring high local drug concentrations while minimizing systemic exposure. Intravitreal injections are commonly used to treat retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and infectious endophthalmitis.
The global intravitreal injectable market has experienced steady growth in recent years, driven primarily by the rising prevalence of retinal disorders such as macular edema, age-related macular degeneration (AMD), and retinal vein occlusion (RVO). Leading pharmaceutical players in this space include Regeneron Pharmaceuticals (notably with Eylea), Allergan, EyePoint Pharmaceuticals, Genentech, and Kanghong Pharmaceutical. These top five companies collectively account for over 70% of global market share, reflecting a relatively concentrated competitive landscape. North America currently dominates the global market, holding a share of more than 50%, followed by Europe and Asia-Pacific, each with shares exceeding 40%.
In terms of drug types, anti-VEGF (vascular endothelial growth factor) therapies represent the largest and most significant market segment, contributing to over 85% of total market revenue. These agents are highly effective in inhibiting abnormal blood vessel growth in the retina, making them the standard of care for diseases like AMD and diabetic macular edema (DME). Other therapeutic classes such as corticosteroids and antibiotics play smaller roles, typically in more specialized or adjunctive treatment scenarios.
The largest clinical application of intravitreal injectables is for macular edema, which continues to see a rise in incidence linked to diabetes and aging populations worldwide. Macular degeneration and RVO are also major contributors to demand, reinforcing the importance of targeted ophthalmic treatments. The increase in awareness, earlier diagnosis, and improved accessibility to eye care services are further driving market expansion across both developed and emerging regions.
Looking ahead, the market is expected to grow steadily due to increasing disease burden and product innovation. Notably, new players such as Astellas Pharma have begun entering the market, signaling a shift toward broader competition and possibly next-generation therapies with extended efficacy and dosing intervals. Advances in drug delivery systems, longer-acting formulations, and biosimilars are expected to further shape the landscape and offer new growth opportunities.
This report aims to provide a comprehensive presentation of the global market for Intravitreal Injectable, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Intravitreal Injectable by region & country, by Drug, and by Disease.
The Intravitreal Injectable market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intravitreal Injectable.
Market Segmentation
By Company
Regeneron Pharmaceuticals (Eylea)
Allergan
EyePoint Pharmaceuticals
Genentech
Kanghong Pharmaceutical
Astellas Pharma
Clearside Biomedical
Bayer
Segment by Drug
Anti-VEGF
Steroids
Others
Segment by Disease
Macular Degeneration
Macular Edema
Uveitis
Retinal Vein Occlusion
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Intravitreal Injectable company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Drug, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Disease, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Intravitreal Injectable in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Intravitreal Injectable in country level. It provides sigmate data by Drug, and by Disease for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index